Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 5:02 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 3,151 matching trials from the live ClinicalTrials.gov search.
Filters: San Antonio, Texas Clear all
Completed Phase 1 Interventional

Irinotecan Plus Mitomycin in Treating Patients With Advanced Solid Tumors

NCT00003710
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
irinotecan hydrochloride, mitomycin C
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2001
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 9, 2012 · Synced Nov 3, 2026, 5:02 AM EST
Completed Phase 2 Interventional

Apitox, Honeybee Venom Treatment for Osteoarthritis Pain and Inflammation

NCT00949754
View directory record Official record
Conditions
Osteoarthritis of the Knee
Interventions
honeybee venom (Apitoxin (Korea) Apitox (USA))
Drug
Lead sponsor
Apimeds, Inc.
Industry
Eligibility
35 Years to 85 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
4
States / cities
Pinellas Park, Florida • Chicago, Illinois • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated May 5, 2010 · Synced Nov 3, 2026, 5:02 AM EST
Terminated No phase listed Observational Accepts healthy volunteers

PASCUAL (Prostate Assay Specific Clinical Utility at Launch) Study

NCT02250313
View directory record Official record
Conditions
Prostate Cancer
Interventions
Not listed
Lead sponsor
MDx Health
Industry
Eligibility
40 Years to 75 Years · Male only
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
15
States / cities
Homewood, Alabama • San Diego, California • Torrance, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2018 · Synced Nov 3, 2026, 5:02 AM EST
Recruiting Phase 4 Interventional

Nuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Needing FVIII Treatment for Surgery

NCT05936580
View directory record Official record
Conditions
Hemophilia A
Interventions
Nuwiq
Drug
Lead sponsor
Octapharma
Industry
Eligibility
12 Years and older · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Nov 3, 2026, 5:02 AM EST
Completed Phase 3 Interventional Results available

A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Lower Risk Myelodysplastic Syndrome (MDS) Without Del 5q

NCT01029262
View directory record Official record
Conditions
Anemia
Interventions
Lenalidomide, Placebo
Drug · Other
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
7
States / cities
Los Angeles, California • Centralia, Illinois • Lebanon, New Hampshire + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2019 · Synced Nov 3, 2026, 5:02 AM EST
Recruiting Phase 3 Interventional

Anticoagulation in ICH Survivors for Stroke Prevention and Recovery

NCT03907046
View directory record Official record
Conditions
Intracerebral Hemorrhage, Atrial Fibrillation
Interventions
Apixaban, Aspirin
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
186
States / cities
Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 141 more
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Nov 3, 2026, 5:02 AM EST
Terminated Phase 2 Interventional Results available

Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis

NCT06097260
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
PLN-74809, Placebo
Drug
Lead sponsor
Pliant Therapeutics, Inc.
Industry
Eligibility
40 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
79
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Nov 3, 2026, 5:02 AM EST
Completed Phase 1 Interventional

Irofulven in Treating Children With Recurrent or Refractory Solid Tumors

NCT00003370
View directory record Official record
Conditions
Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
irofulven
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
51
States / cities
Little Rock, Arkansas • Duarte, California • La Jolla, California + 41 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2013 · Synced Nov 3, 2026, 5:02 AM EST
Recruiting Phase 1 Interventional

Dose Escalation and Expansion Study of BH3120 Alone or With Pembrolizuamb in Advanced or Metastatic Solid Tumors

NCT06234397
View directory record Official record
Conditions
Advanced or Metastatic Solid Tumors
Interventions
BH3120, pembrolizumab
Drug
Lead sponsor
Hanmi Pharmaceutical Company Limited
Industry
Eligibility
18 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
5
States / cities
Tampa, Florida • Grand Rapids, Michigan • Cincinnati, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Nov 3, 2026, 5:02 AM EST
Recruiting Phase 3 Interventional

Dichoptic Treatment for Amblyopia in Children 8 to 12 Years of Age

NCT06524882
View directory record Official record
Conditions
Amblyopia
Interventions
Vivid Vision, Luminopia, Optical Correction
Device
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
8 Years to 12 Years
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
58
States / cities
Birmingham, Alabama • Glendale, Arizona • Scottsdale, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 3, 2026, 5:02 AM EST
Completed Not applicable Interventional Results available

Checklist to Prevent MRSA Surgical Site Infections

NCT02216227
View directory record Official record
Conditions
Surgical Site Infection
Interventions
Mupirocin, Chlorhexidine gluconate, Cefazolin, Vancomycin, Nasal Povidone Iodine
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
23,005 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
11
States / cities
Miami, Florida • Iowa City, Iowa • Baltimore, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Nov 3, 2026, 5:02 AM EST
Not listed Not applicable Interventional

Evaluation of a Self-Care Toolkit in Surgical Breast Cancer Patients

NCT02387320
View directory record Official record
Conditions
Anxiety, Pain, Nausea, Fatigue, Sleep Disturbance
Interventions
Self-Care Toolkit
Other
Lead sponsor
Samueli Institute for Information Biology
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
2
States / cities
Fort Hood, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 12, 2016 · Synced Nov 3, 2026, 5:02 AM EST
Completed Phase 3 Interventional Results available

Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer

NCT00980460
View directory record Official record
Conditions
PRETEXT I Hepatoblastoma, PRETEXT II Hepatoblastoma, PRETEXT III Hepatoblastoma, PRETEXT IV Hepatoblastoma
Interventions
Cisplatin, Dexrazoxane, Doxorubicin Hydrochloride, Fluorouracil, Irinotecan Hydrochloride, Laboratory Biomarker Analysis, Liver Transplantation, Temsirolimus, Therapeutic Conventional Surgery, Vincristine Sulfate
Drug · Other · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2026
U.S. locations
184
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 133 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Nov 3, 2026, 5:02 AM EST
Active, not recruiting Phase 3 Interventional

Comparing Radiation Therapy to Usual Treatment for Patients With High-Risk Bone Metastases That Are Not Causing Pain, PREEMPT Trial

NCT06745024
View directory record Official record
Conditions
Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Solid Neoplasm
Interventions
Best Practice, Biospecimen Collection, Bone Metastases Treatment, Computed Tomography, Conventional Radiotherapy, Magnetic Resonance Imaging, Patient Observation, Questionnaire Administration, Stereotactic Body Radiation Therapy
Other · Procedure · Radiation
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
624
States / cities
Fairbanks, Alaska • Gilbert, Arizona • Phoenix, Arizona + 450 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Nov 3, 2026, 5:02 AM EST
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of BIIB104 in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS)

NCT03745820
View directory record Official record
Conditions
Cognitive Impairment Associated With Schizophrenia
Interventions
BIIB104, Placebo
Drug · Other
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
37
States / cities
Bentonville, Arkansas • Culver City, California • Garden Grove, California + 31 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Nov 3, 2026, 5:02 AM EST
Completed Phase 2 Interventional

Fenretinide in Treating Patients With Recurrent Malignant Glioma

NCT00006080
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
fenretinide
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
11
States / cities
Los Angeles, California • San Francisco, California • Bethesda, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2018 · Synced Nov 3, 2026, 5:02 AM EST
Completed Phase 2 Interventional

S9805, High-Dose Melphalan Plus Peripheral Stem Cell Transplantation Followed by Interferon Alfa in Treating Patients With Waldenstrom's Macroglobulinemia

NCT00003416
View directory record Official record
Conditions
Lymphoma
Interventions
filgrastim, recombinant interferon alfa, dexamethasone, melphalan, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Up to 69 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
84
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 55 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2015 · Synced Nov 3, 2026, 5:02 AM EST
Completed Phase 3 Interventional

A Study of Three Different Anti-HIV Drug Combinations in HIV-Infected Patients

NCT00002410
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Lamivudine, Zidovudine
Drug
Lead sponsor
Dupont Merck
Industry
Eligibility
13 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
40
States / cities
Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Nov 3, 2026, 5:02 AM EST
Recruiting Not applicable Interventional

Sirolimus Coated BALloon Versus Standard Balloon Angioplasty in The Treatment of Below The Knee Arterial Disease

NCT06182397
View directory record Official record
Conditions
Arterial Disease of Legs, Below-the-knee Obstruction, PAD - Peripheral Arterial Disease
Interventions
MagicTouch PTA Sirolimus drug coated balloon, Placebo balloon angioplasty
Device
Lead sponsor
Concept Medical Inc.
Industry
Eligibility
21 Years and older
Enrollment
368 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
29
States / cities
Scottsdale, Arizona • Los Angeles, California • Clearwater, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2026 · Synced Nov 3, 2026, 5:02 AM EST
Completed Phase 2 Interventional

Docetaxel in Treating Children With Relapsed or Refractory Acute Lymphoblastic or Acute Myeloid Leukemia

NCT00021242
View directory record Official record
Conditions
Leukemia
Interventions
docetaxel
Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 21 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
200
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 148 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2014 · Synced Nov 3, 2026, 5:02 AM EST
Completed Phase 2 Interventional Results available

CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma

NCT03428217
View directory record Official record
Conditions
Advanced Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma
Interventions
CB-839, Cabozantinib, Placebo
Drug
Lead sponsor
Calithera Biosciences, Inc
Industry
Eligibility
18 Years and older
Enrollment
444 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
59
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2023 · Synced Nov 3, 2026, 5:02 AM EST
Completed Phase 2 Interventional Results available

Vascular Endothelial Growth Factor-B (VEGF-B) Blockade With the Monoclonal Antibody CSL346 in Subjects With Diabetic Kidney Disease

NCT04419467
View directory record Official record
Conditions
Diabetic Kidney Disease (DKD)
Interventions
CSL346, Placebo
Biological · Drug
Lead sponsor
CSL Behring
Industry
Eligibility
25 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
22
States / cities
Covina, California • Fresno, California • Lomita, California + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2023 · Synced Nov 3, 2026, 5:02 AM EST
Recruiting No phase listed Observational

Quality of Pediatric Resuscitation in a Multicenter Collaborative

NCT02708134
View directory record Official record
Conditions
Cardiac Arrest, Cardiopulmonary Arrest
Interventions
Not listed
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
0 Years to 18 Years
Enrollment
7,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2030
U.S. locations
42
States / cities
Los Angeles, California • Madera, California • Orange, California + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Nov 3, 2026, 5:02 AM EST
Completed Phase 3 Interventional Results available

A Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients With Open-Angle Glaucoma or Ocular Hypertension

NCT02636946
View directory record Official record
Conditions
Glaucoma, Open-Angle Ocular Hypertension
Interventions
Bimatoprost SR, Sham Bimatoprost SR, Selective Laser Trabeculoplasty, Sham Selective Laser Trabeculoplasty
Drug · Procedure
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
21
States / cities
Dothan, Alabama • Chandler, Arizona • Redding, California + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2022 · Synced Nov 3, 2026, 5:02 AM EST